Reports
Reports
Annual Drug Utilization Reports
Drug Utilization Reports offer data regarding dispensed controlled substance prescriptions reported to MAPS. In 2020, the number of opioid prescriptions dispensed decreased by 38.5 percent since 2015. Effective January 4, 2019, gabapentin was classified as a Schedule 5 controlled substance and accounts for 2,271,317 (12.3%) of all 2019 controlled substance prescriptions reported to MAPS, and 2,297,670 (12.9%) of all 2020 controlled substance prescriptions reported to MAPS.
-
Total CS prescriptions dispensed
% change from previous year
2007
17,007,858
2008
17,400,640
2.31%
2009
17,876,684
2.74%
2010
18,954,172
6.03%
2011
19,763,680
4.27%
2012
20,991,020
6.21%
2013
20,728,216
-1.25%
2014
20,904,764
0.85%
2015
21,472,326
2.71%
2016
21,092,674
-1.77%
2017 19,943,203 -5.45% 2018 (updated Nov 5, 2019)
17,623,754
-11.63%
2019 18,472,677 4.82% 2020 17,785,603 -3.72% Select the years below to access individual drug utilization reports.
2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 (Updated Nov 5, 2019) 2019 2020
State Opioid Assessment
A new statewide assessment has identified trends that will assist government agencies, lawmakers and local community leaders tailor laws, target resources, and design innovative programs to best address the opioid epidemic in Michigan.
The assessment overlays three years (2013-2015) of well-documented cases of unintentional overdose death with five years (2012-2017) of prescription records in the Michigan Automated Prescription System (MAPS). In total, more than 7.5 million patients receiving 103.2 million prescriptions over the last five years were linked to 5,261 overdose deaths.
The assessment provides valuable information about patterns of opioid usage in Michigan by detailing patient-level and aggregate trends of controlled-substance prescriptions and overdose deaths within the state.
NarxCare Effectiveness Study
- Narxcare Effectiveness Study Introduction
A new study, the Michigan AWARxE/NarxCare Implementation Evaluation, is the nation’s first study evaluating the effectiveness of NarxCare. Appriss’s Michigan Implementation and Evaluation analyzes NarxCare risk scores and shows a decline in patients with a high potential to abuse prescription drugs.
MAPS Resources
Contact MAPS
- Contact Maps Info
Telephone: 517-241-0166
Fax: 517-241-5072
Email: BPL-MAPS@michigan.gov
MAPS Integration
- MAPS Partners
The State of Michigan is covering the full cost of integration of MAPS into the clinical workflow of health systems, physician groups and pharmacies until August 31, 2020. Learn how to start the integration process.
MAPS Legislation
- MAP Legislation Info
If your question(s) pertain to the new opioid legislation, we encourage you to review the recently-released FAQs. Additional questions or concerns can be addressed by contacting MAPS.
- MAPS Partners
- MAPS logo
Copyright 2021 State of Michigan